Menofem

Cimicifuga racemosa (black cohosh) dry extract, the active ingredient in Menofem, is a herbal botanical presented as a dry extract for oral use. It is intended to help adult women manage common menopausal symptoms, including hot flashes, night sweats, and occasional mood changes.

GNH USA supplies Menofem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers through established distribution networks and regulatory support.

Menofem, a black cohosh dry extract, is used to alleviate symptoms associated with the menopausal transition. - Hot flashes: reduction in frequency and intensity of sudden warmth episodes. - Night sweats: decrease in the number and volume of nocturnal perspiration episodes. - Mood swings: improvement in emotional stability and reduction of irritability.

Menofem is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Mild gastrointestinal upset, such as nausea or stomach discomfort. - Headache or light‑headedness. - Dizziness, especially when standing quickly. - Skin rash or mild itching.

Serious or Rare Side Effects: - Liver injury presenting as jaundice or elevated enzymes. - Severe allergic reaction, including swelling of the face or throat. - Unexplained bleeding or bruising.

Menofem should be used with awareness of the following precautions. - Pregnancy: safety not established; avoid use during pregnancy. - Breastfeeding: caution advised as transfer to milk is unknown. - Known allergy to black cohosh: discontinue use immediately. - Concurrent hormone therapy: monitor for additive estrogenic effects. - Pre‑existing liver disease: use only under medical supervision. - Store at ambient temperature: keep in the original pack, protect from moisture.

Potential drug interactions with Menofem should be considered.

Major Interactions (Avoid): - Hormone replacement therapy: may increase overall estrogenic activity. - Anticoagulants (e.g., warfarin): possible heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): potential serotonergic interaction. - Antihypertensive agents: may affect blood pressure control. - CYP450 substrate drugs: possible alteration of metabolism leading to changed plasma levels.